NCT03267836View on ClinicalTrials.gov

Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 10, 2018

Primary Completion Date

April 6, 2023

Study Completion Date

April 6, 2023

Conditions
MeningiomaMeningioma, Adult
Interventions
DRUG

Avelumab

-10mg/kg IV

RADIATION

Proton Therapy

-Proton therapy will start concurrently with the first dose of avelumab (up to 3 days before or after is permissible) and will be administered once daily during weekdays (Monday through Friday).

PROCEDURE

Surgery

-Standard of care

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT03267836 - Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma | Biotech Hunter | Biotech Hunter